Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Stock Has Consensus Price Target of $7.67

Key Points

• Polaryx Therapeutics has a “Moderate Buy” consensus rating from five analysts, with two buys, one strong buy, one hold, and one sell. The average 12-month price target is $7.67.
• PLYX shares opened at $2.02, down 2.4%, with a market capitalization of about $100.7 million; the stock has traded between $1.85 and $48.91 over the past year.
• The company reported a quarterly loss of $0.03 per share, beating analyst expectations for a $0.05 loss. Analysts expect a full-year loss of approximately $0.22 per share.

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.67.

Several equities analysts recently commented on PLYX shares. Weiss Ratings reissued a "sell (e)" rating on shares of Polaryx Therapeutics in a research note on Monday. Wall Street Zen upgraded shares of Polaryx Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. Zacks Research upgraded Polaryx Therapeutics to a "hold" rating in a research note on Friday, July 10th. Raymond James Financial initiated coverage on Polaryx Therapeutics in a report on Thursday, August 13th. They set a "strong-buy" rating and a $6.00 price objective on the stock. Finally, HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They set a "buy" rating and a $7.00 price objective on the stock.

Polaryx Therapeutics Trading Down 2.4%

Shares of NASDAQ PLYX opened at $2.02 on Friday. The company has a market cap of $100.70 million and a price-to-earnings ratio of -25.25. Polaryx Therapeutics has a 12 month low of $1.85 and a 12 month high of $48.91. The stock has a 50-day moving average price of $2.10 and a two-hundred day moving average price of $3.29.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. On average, sell-side analysts predict that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.